Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Needlestick and occupational exposure

Essential points for quick revision.

Saved on this device
!
Potential HIV exposure is time critical

A percutaneous or mucocutaneous exposure to blood or another potentially infectious fluid may require HIV PEP before source results are available.

Action: Wash or irrigate immediately, report the incident, obtain urgent expert risk assessment, draw consented baseline tests and start HIV PEP when indicated as soon as possible, preferably within 24 hours and no later than 72 hours.

Synopsis

Give immediate first aid, classify blood-borne-virus exposure by fluid and route, start indicated HIV PEP inside its window, and arrange hepatitis and follow-up care.

  • First aid is immediate: encourage gentle bleeding from a puncture, wash with soap and running water, irrigate eyes or mouth with water, and never suck, scrub or use bleach on the wound.
  • A significant occupational route is percutaneous inoculation, mucous-membrane splash or contact with non-intact skin; intact-skin contact alone is not an HIV exposure.
  • Potentially infectious material includes blood and visibly blood-stained fluid. Urine, saliva, vomit, sweat, tears and faeces without visible blood do not justify HIV PEP.

Key red flags

A deep injury, hollow-bore needle, device visibly contaminated with blood or needle previously in a vessel increases inoculum and urgency.

Blood splash to eye or mouth, or blood contacting eczema, abrasion or another break in skin, is a mucocutaneous exposure even without a needle.

Known untreated or detectably viraemic HIV in the source makes a qualifying route high priority; do not wait for full resistance information. PEP is generally not recommended for a treated source only when ART has been taken for at least six months, the last HIV RNA is below 200 copies/mL and was measured within the previous six months, and adherence is good. Seek expert advice for stale or uncertain data, resistance or a major inoculation.

The source may carry hepatitis B or C even when HIV risk is low; complete a three-virus assessment and verify hepatitis B vaccination response.

The exposed worker may be pregnant, have renal disease or take interacting medicines; tailor the regimen without delaying an indicated first dose.

Percutaneous inoculation

Needlestick, scalpel injury or bite that breaks skin and involves blood creates direct access to tissue and requires urgent BBV assessment.

Mucosal splash

Blood entering an eye, mouth or nose is a qualifying route; irrigate immediately and assess source infectivity and volume.

Non-intact skin contact

Blood contacting eczema, abrasion, dermatitis or an open wound can qualify even when the worker did not feel a sharp injury.

High-inoculum feature

Deep injury, hollow-bore device, visible blood and prior placement in an artery or vein increase the amount potentially transmitted.

Investigation priorities

01
Exposure description and source assessmentFirst step

Record time, device, depth, fluid, route, protective equipment and source HIV, HBV and HCV information.

Management branches

Immediate exposure pathwayClean, report and classify

A sharp injury or splash occurs while handling blood or body fluid at work.

  1. Stop the task safely, encourage gentle bleeding of a puncture, wash with soap and water or irrigate exposed mucosa, and avoid caustic chemicals.
  2. Report immediately through occupational health or the out-of-hours route; document fluid, route, time, device and inoculum features.

Key medicines

HIV post-exposure prophylaxisStart the current recommended three-drug oral regimen immediately and continue for 28 days; use the specialist alternative selected for renal disease, pregnancy, interactions or source resistance.Check baseline HIV status, renal and hepatic function, pregnancy, hepatitis B, interacting antacids and medicines; do not delay initiation while non-immediate results are pending.
Hepatitis B vaccine and immunoglobulinGive vaccine booster or course and, when indicated, hepatitis B immunoglobulin at the current Green Book dose and timing for the source category and documented responder status.HBIG does not prevent HIV or HCV; use documented anti-HBs and HBsAg information, and arrange completion plus post-vaccination testing where required.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom